March 2010
Practice Tip: FDA Issues Draft Guidance for REMSPart One of a Two-Part Article
By Alan G. Minsk and Lanchi Nguyen
On Sept. 30, 2009, the FDA issued a draft guidance for industry on better understanding and implementing Risk Evaluation and Mitigation Strategies (REMS), which the FDA requires for certain drugs or biologics.
Subscribers: click here for the full story
Non-Subscribers: click here to subscribe
Pay per view ($20.00)
